Clinical Trial Update: TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. [Phase 3]

View source ↗

Summary

A randomized Phase III trial evaluating second-line therapy with aflibercept, irinotecan (Day 1 or Day 1,3), 5-fluorouracil, and folinic acid for metastatic col…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Aflibercept (Aflibercept)
• Folinic acid (folinic acid)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Hôpital Franco-Britannique-Fondation Cognacq-Jay | Conditions: Cancer Colorectal, Metastasis | Phase 3 | Status: UNKNOWN